For research use only. Not for therapeutic Use.
Pirfenidone (Cat.No:I003946) is an orally administered medication approved for the treatment of idiopathic pulmonary fibrosis (IPF). It exerts its therapeutic effects through its anti-fibrotic, anti-inflammatory, and antioxidant properties. Pirfenidone helps slow the progression of IPF, reducing lung function decline and improving overall quality of life for patients with this debilitating lung disease.
| Catalog Number | I003946 |
| CAS Number | 53179-13-8 |
| Synonyms | 5-methyl-1-phenylpyridin-2-one |
| Molecular Formula | C12H11NO |
| Purity | ≥95% |
| Target | SMAD |
| Solubility | DMSO 37 mg/mL; Water <1 mg/mL |
| Storage | 3 years -20C powder |
| InChI | InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3 |
| InChIKey | ISWRGOKTTBVCFA-UHFFFAOYSA-N |
| SMILES | CC(C=C1)=CN(C2=CC=CC=C2)C1=O |
| Reference | </br>1:Pirfenidone: a breath of fresh air for cGVHD. Ranganathan P.Blood. 2017 May 4;129(18):2463-2464. doi: 10.1182/blood-2017-03-772103. No abstract available. PMID: 28473413 </br>2:Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR.Am J Respir Crit Care Med. 2017 May 4. doi: 10.1164/rccm.201701-0091OC. [Epub ahead of print] PMID: 28471697 </br>3:Pirfenidone normalizes the tumor microenvironment to improve chemotherapy. Polydorou C, Mpekris F, Papageorgis P, Voutouri C, Stylianopoulos T.Oncotarget. 2017 Apr 11;8(15):24506-24517. doi: 10.18632/oncotarget.15534. PMID: 28445938 Free PMC Article</br>4:Tolerability of treatment with pirfenidone or nintedanib for pulmonary fibrosis in the real world. Ogura T, Kitamura H.Respirology. 2017 Apr 25. doi: 10.1111/resp.13059. [Epub ahead of print] No abstract available. PMID: 28440554 Free Article</br>5:Role of pirfenidone in the management of pulmonary fibrosis. Meyer KC, Decker CA.Ther Clin Risk Manag. 2017 Apr 3;13:427-437. doi: 10.2147/TCRM.S81141. eCollection 2017. Review. PMID: 28435277 Free PMC Article</br>6:Pirfenidone for acute exacerbation of idiopathic pulmonary fibrosis: A retrospective study. Furuya K, Sakamoto S, Shimizu H, Sekiya M, Kinoshita A, Isshiki T, Sugino K, Matsumoto K, Homma S.Respir Med. 2017 May;126:93-99. doi: 10.1016/j.rmed.2017.03.026. Epub 2017 Mar 29. PMID: 28427556 </br>7:Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. Liu Y, Lu F, Kang L, Wang Z, Wang Y.BMC Pulm Med. 2017 Apr 18;17(1):63. doi: 10.1186/s12890-017-0405-7. PMID: 28420366 Free PMC Article</br>8:Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Kreuter M, Spagnolo P, Wuyts W, Renzoni E, Koschel D, Bonella F, Maher TM, Kolb M, Weycker D, Kirchgässler KU, Costabel U.Respiration. 2017 Apr 12. doi: 10.1159/000468546. [Epub ahead of print] PMID: 28399537 Free Article</br>9:Pirfenidone and nintedanib for pulmonary fibrosis in clinical practice: Tolerability and adverse drug reactions. Galli JA, Pandya A, Vega-Olivo M, Dass C, Zhao H, Criner GJ.Respirology. 2017 Mar 20. doi: 10.1111/resp.13024. [Epub ahead of print] PMID: 28317233 </br>10:Pirfenidone inhibits post-traumatic proliferative vitreoretinopathy. Khanum BN, Guha R, Sur VP, Nandi S, Basak SK, Konar A, Hazra S.Eye (Lond). 2017 Mar 17. doi: 10.1038/eye.2017.21. [Epub ahead of print] PMID: 28304388 |
